XETR
M12
Market cap422mUSD
Oct 09, Last price
19.88EUR
1D
-1.09%
1Q
9.83%
Jan 2017
88.53%
IPO
282.31%
Name
M1 Kliniken AG
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
M1 Kliniken AG, a Berlin, Germany-based entity established in 2007 and operating as a subsidiary of MPH Health Care AG, manages medical facilities dedicated to aesthetic and plastic surgery across Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company's operations are segmented into two core divisions: Beauty and Trade. The Beauty segment is responsible for the creation and commercialization of pharmaceutical, medical, and medical technology products tailored for aesthetic medicine and cosmetic dermatology. Meanwhile, the Trade segment engages in the distribution of pharmaceuticals, biosimilars, and other medical products and devices, serving critical therapeutic areas such as oncology, HIV, rheumatology, neurology, cardiovascular conditions, and narcotics. Products are supplied to healthcare professionals, pharmacies, and wholesale distributors under the "M1 Select" brand. M1 Kliniken AG's operational footprint encompasses a network of outpatient specialist centers, a specialized surgical clinic center, and 46 distinct specialist locations branded as "M1 Med Beauty." Additionally, the company is involved in the acquisition, administration, and divestiture of real estate, predominantly within the healthcare industry.
Related entities
Subsidiaries
M1 Med Beauty Berlin GmbH
Key people
Albert Wahl
Chairman of the Supervisory Board · since 2017
Chief Executive Officer, Member of the Management Board · since 2015
Uwe Zimdars
Deputy Chairman of the Supervisory Board · since 2017
Sabine Meck
Member of the Supervisory Board · since 2015
Headquarters & legal address
Grünauer Straße 5
Berlin, BE 12557
DE
Berlin, BE 12557
DE
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||